Inclusion Criteria:

        • Histologically documented diagnosis of CD38 (cluster of differentiation 38) positive
        PTCL-NOS, AITL and other nodal lymphomas of TFH cell origin as defined in the 2017 edition
        of the World Health Organization (WHO) classification. Patients with only bone marrow
        involvement are eligible.

        Note: Only patients with a centrally assessed percentage of CD38 positive tumor cells ≥ 5%
        in the relapse biopsy, or in the more recent biopsy in the case of refractory patients,
        will be considered eligible for protocol study treatment.

          -  Age 18-75 years

          -  Relapsed or refractory to at least one and a maximum of two previous lines of
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

          -  At least one site of measurable nodal disease at baseline ≥ 2.0 cm in the longest
             transverse diameter as determined by CT scan (MRI is allowed only if CT scan cannot be
             performed). Note: Patients with only bone marrow involvement are eligible

          -  Adequate hematological counts defined as follows:

               -  Absolute Neutrophil count (ANC) > 1.0 x 109/L unless due to bone marrow
                  involvement by lymphoma

               -  Platelet count ≥ 50.000/mm3 unless due to bone marrow involvement by lymphoma

          -  Adequate renal function defined as follows:

             - Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)

          -  Adequate hepatic function per local laboratory reference range as follows:

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit
                  of normal (ULN)

               -  Bilirubin ≤1.5 x upper limit of normal (ULN)(unless bilirubin rise is due to
                  Gilbert's syndrome or of non-hepatic origin)

          -  Subject understands and voluntarily signs an informed consent form approved by an
             Independent Ethics Committee (IEC), prior to the initiation of any screening or
             study-specific procedures

          -  Subject must be able to adhere to the study visit schedule and other protocol
             requirements

          -  Life expectancy ≥ 3 months

          -  Women must be:

               -  postmenopausal for at least 1 year (must not have had a natural menses for at
                  least 12 months)

               -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
                  ligation, or otherwise be incapable of pregnancy),

               -  completely abstinent (periodic abstinence from intercourse is not permitted) or
                  if sexually active, be practicing two highly effective methods of birth control
                  (e.g., prescription oral contraceptives, contraceptive injections, contraceptive
                  patch, intrauterine device, double barrier method (e.g.: condoms, diaphragm, or
                  cervical cap, with spermicidal foam, cream, or gel, male partner sterilization)
                  as local regulations permit, before entry, and must agree to continue to use the
                  same method of contraception throughout the study. They must also be prepared to
                  continue birth control measures for at least 3 months after terminating
                  treatment.

               -  Women of childbearing potential must have a negative pregnancy test at screening

          -  Men must agree to use an acceptable method of contraception (for themselves or female
             partners as listed above) for the duration of the study. Men must agree to use a
             double barrier method of birth control and to not donate sperm during the study and
             for 3 months after receiving the last dose of study drug.

          -  Male even if surgically sterilized (i.e., status post vasectomy) must agree to 1 of
             the following:

               -  practice effective barrier contraception during the entire study treatment period
                  and through 3 months after the last dose of study drug, or

               -  agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,
                  symptothermal, post ovulation methods for the female partner] and withdrawal are
                  not acceptable methods of contraception)

        Exclusion Criteria:

          -  Histological diagnosis different from CD38 positive PTCL-NOS, AITL, and other nodal
             lymphomas of TFH cell origin

          -  More than two lines of previous treatment (autologous stem cell transplant performed
             as part of consolidation to a previous line of therapy should not be considered as a
             line of therapy)

          -  Previous treatment with Gemcitabine or Platinum based regimens; patients who received
             a single course of Platinum based course (i.e. DHAP) are not excluded

          -  Prior therapy with monoclonal antibody anti CD38 (against cluster of differentiation
             38)

          -  Concomitant experimental therapy

          -  Relapse after allo SCT

          -  Central nervous system (CNS) involvement with lymphoma

          -  Subject has received any anti-cancer therapy including chemotherapy, immunotherapy,
             radiotherapy, investigational therapy, including targeted small molecule agents within
             14 days prior to the first dose of study drug

          -  Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment

          -  Subject is:

               -  Known to be seropositive for human immunodeficiency virus (HIV)

               -  Seropositive for hepatitis B (defined by a positive test for hepatitis B surface
                  antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg
                  negative but positive for antibodies to hepatitis B core antigen [anti-hepatitis
                  B core antigen (HBc)] ± antibodies to hepatitis B surface antigen [anti-HBs])
                  must be screened using real-time polymerase chain reaction (PCR) measurement of
                  hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.
                  EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination
                  (anti-HBs positivity as the only serologic marker) AND a known history of prior
                  HBV vaccination, do not need to be tested for HBV DNA by PCR

               -  Known to be seropositive for hepatitis C (except in the setting of a Sustained
                  Virologic Response(SVR), defined as aviremia at least 12 weeks after completion
                  of antiviral therapy)

          -  Cardiovascular disease (NYHA class ≥2)

          -  Creatinine Clearance < 40 mL/min (Cockcroft-Gault formula)

          -  Significant history of neurologic, psychiatric, endocrinological, metabolic,
             immunologic, or hepatic disease that would preclude participation in the study or
             compromise ability to give informed consent

          -  Any history of other active malignancies within 3 years prior to study entry, with the
             exception of adequately treated in situ carcinoma of the cervix uterine, basal cell
             carcinoma of the skin or localized squamous cell carcinoma of the skin, previous
             malignancy confined and surgically resected with curative intent.

          -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal)

          -  Evidence of any other clinically significant uncontrolled condition(s)

          -  If female, the patient is pregnant or breast-feeding